首页|不同配比哌拉西林钠他唑巴坦钠在重症肺炎治疗中的安全性及影响因素研究

不同配比哌拉西林钠他唑巴坦钠在重症肺炎治疗中的安全性及影响因素研究

扫码查看
原文链接
  • 万方数据
  • 维普
目的:探讨不同配比哌拉西林钠他唑巴坦钠在重症肺炎患者治疗中的安全性及其影响因素。方法:回顾性调查 2021 年8 月至 2022 年 8 月中国医科大学附属第一医院应用不同配比哌拉西林钠他唑巴坦钠治疗的重症肺炎患者的不良反应(粒细胞缺乏、血小板计数降低、过敏和腹泻)发生情况。根据治疗方案(复方制剂相关配比)分为治疗 1 组[采用哌拉西林钠他唑巴坦钠(4∶1)治疗]和治疗 2 组[采用哌拉西林钠他唑巴坦钠(8∶1)治疗]。统计分析患者年龄、性别、既往疾病、用药剂量、用药疗程等与各不良反应相关性。结果:治疗 1 组患者的总不良反应发生率为 79。61%(609/765)，低于治疗 2 组(84。55%，476/563)，差异有统计学意义(P<0。05)。单因素 Logistic回归分析结果显示，哌拉西林钠他唑巴坦钠(8 ∶1)的复方制剂配比(OR=1。098，P= 0。012)、住院时间延长(OR=1。029，P<0。001)是不良反应发生的独立危险因素(P<0。05);多因素Logistic回归分析结果显示，年龄增长(OR=1。012，P=0。011)、用药疗程延长(OR=1。036，P=0。013)是总不良反应发生的影响因素。结论:哌拉西林钠他唑巴坦钠(4∶1)治疗重症肺炎具有更高的安全性。较长的用药疗程和住院时间可能增加应用哌拉西林钠他唑巴坦钠治疗患者的不良反应发生风险。
Safety and Influencing Factors of Different Proportions of Piperacillin Sodium and Tazobactam Sodium in the Treatment of Severe Pneumonia
OBJECTIVE:To probe into the safety and influencing factors of different proportions of piperacillin sodium and tazobactam sodium in the treatment of severe pneumonia patients.METHODS:Incidence of adverse drug reactions(granulocytopenia,decreased platelet count,allergy and diarrhea)in patients with severe pneumonia treated with different proportions of piperacillin sodium and tazobactam sodium in the First Affiliated Hospital of China Medical University from Aug.2021 to Aug.2022 was retrospectively reviewed.According to the treatment regimen(related proportion of compound preparations),all patients were divided into the treatment group 1[with piperacillin sodium and tazobactam sodium(4 ∶1)]and treatment group 2[with piperacillin sodium and tazobactam sodium(8 ∶1)].Correlation between age,gender,previous disease,dosage,medication duration and adverse drug reactions was statistically analyzed.RESULTS:The incidence of adverse drug reactions in treatment group 1 was 79.61%(609/765),which was lower than 84.55%(476/563)in treatment group 2,the difference was statistically significant(P<0.05).Univariate Logistic regression analysis showed that the combination ratio of piperacillin sodium and tazobactam sodium 8 ∶1(OR=1.098,P=0.012)and prolonged length of stay(OR=1.029,P<0.001)were independent risk factors for adverse drug reactions(P<0.05).Multivariate Logistic regression analysis showed that age increase(OR=1.012,P=0.011)and prolonged medication duration(OR = 1.036,P = 0.013)were risk factors of total adverse drug reactions.CONCLUSIONS:Piperacillin sodium and tazobactam sodium(4∶1)has a higher safety in the treatment of severe pneumonia.Longer medication duration and length of stay may increase the incidence of adverse drug reactions in patients treated with piperacillin sodium and tazobactam sodium.

Piperacillin sodium and tazobactam sodiumAdverse drug reactionSafetyInfluencing factors

孙宁、赵春阳、蔡佳怡、易涵、靖晶、刘运嘉、赵娇、韩峰超、姜明燕

展开 >

中国医科大学附属第一医院药学部,沈阳 110001

中国医科大学药学院,沈阳 110122

沈阳市市场监管事务服务中心沈阳市市场监管安全预警中心 ,沈阳 110001

哌拉西林钠他唑巴坦钠 不良反应 安全性 影响因素

沈阳市药品重点监测项目

SYYJY-2021-01

2024

10.14009/j.issn.1672-2124.2024.02.017

中国医院用药评价与分析
中国医药生物技术协会，中国药房杂志社

中国医院用药评价与分析

CSTPCD
影响因子：1.142
ISSN：1672-2124
年,卷(期)：2024.24(2)
  • 21